Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. develops medical technology for diagnosing and monitoring serious neurological conditions in acute-care settings. Its Ceribell System is a point-of-care electroencephalography, or EEG, platform that combines portable hardware with AI-powered algorithms for rapid brain monitoring in hospitals. The system is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S.
Company updates commonly address quarterly and annual financial results, adoption of the Ceribell System, FDA clearances for the Clarity algorithm and delirium monitoring, and regulatory designations tied to additional neurological indications such as large vessel occlusion stroke. Ceribell also issues announcements on investor conference participation and other public-company communications.
Ceribell (Nasdaq: CBLL) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $22.6M, up 31% year-over-year; product revenue was $17.0M (+28%) and subscription revenue was $5.6M (+44%). Gross margin was 88% and gross profit was $19.9M. Operating expenses rose to $34.6M (+39%), driving a net loss of $13.5M (−$0.37 per share). Cash and marketable securities totaled $168.5M at quarter end. The company ended the quarter with 615 active accounts, appointed Erica Rogers to the board, and raised full‑year 2025 revenue guidance to $87M–$89M (~33%–36% growth).
Ceribell (Nasdaq: CBLL) will release its third quarter 2025 financial results after the close of trading on Tuesday, November 4, 2025.
Company management will host a conference call to discuss results at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Domestic callers can dial (800) 715-9871, international callers (646) 307-1963, and use access code 9394689. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Ceribell (NASDAQ: CBLL), a medical technology company specializing in neurological diagnostics, has appointed Erica Rogers to its Board of Directors. Rogers brings over 30 years of experience in leading medical device companies, most notably as CEO of Silk Road Medical, where she grew the company from a 25-person startup to a 500-employee public company with $175 million in revenue.
Under Rogers' leadership, Silk Road Medical achieved FDA approval and commercial expansion, ultimately leading to its acquisition by Boston Scientific Corporation. Her appointment comes as Ceribell expands its point-of-care EEG system, which is currently used in over 550 hospitals to improve care for critically ill patients.
Ceribell (NASDAQ:CBLL) reported strong Q2 2025 financial results, with total revenue reaching $21.2 million, up 38% year-over-year. The medical technology company achieved an 88% gross margin and expanded to 584 total active accounts.
The company's performance was driven by product revenue of $15.9 million (up 38%) and subscription revenue of $5.3 million (up 41%). Despite these gains, Ceribell reported a net loss of $13.6 million ($0.38 per share) due to increased operating expenses. The company maintains a strong financial position with $177.4 million in cash and equivalents.
Following these results, Ceribell raised its full-year 2025 revenue guidance to $85-88 million, projecting 30-34% growth over 2024.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., will deliver a presentation on Tuesday, August 12, 2025, at 2:00 p.m. EST.
Investors can access both the live and archived versions of the presentation through the company's investor relations website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has scheduled its Q2 2025 financial results release for August 5, 2025, after market close.
The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Investors can join via phone using the provided dial-in numbers and access code 7468193, or access the webcast through Ceribell's investor relations website.
Ceribell (Nasdaq: CBLL) has filed patent infringement complaints against Natus Medical Incorporated with both the U.S. International Trade Commission (USITC) and the U.S. District Court in Delaware. The complaints allege that Natus is infringing on six patents related to Ceribell's EEG headband and electrode design technology.
The company is seeking an exclusion order from USITC to prevent the importation of infringing Natus products into the United States. CEO Jane Chao emphasized Ceribell's significant investments in point-of-care EEG technology and commitment to protecting their intellectual property to continue delivering innovative healthcare solutions.
Ceribell, a medical technology company specializing in neurological diagnostics, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., will deliver a presentation on Wednesday, May 14, 2025, at 10:55 AM PST (1:55 PM EST).
The presentation will be accessible to interested parties through a live webcast, which will also be archived for future reference. Viewers can access the webcast through the Investor Relations section of Ceribell's website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL) focuses on transforming the diagnosis and management of serious neurological conditions through innovative medical technology solutions.